Small Percentage of Ophthalmologists Perform Large Proportion of Intravitreal Anti-VEGF Injections

Source: Reuters Health

Three percent of ophthalmologists perform 17% to 31% of all anti-vascular endothelial growth factor (VEGF) injections in the U.S., depending on the agent used, according to new findings, as reported by Reuters.

“More important, the results are consistent from 2012 to 2015; the data suggest that publication of the CATT results had limited influence on anti-VEGF selection patterns,” Dr. Shriji Patel of Vanderbilt University School of Medicine in Nashville, Tennessee, and colleagues write in JAMA Ophthalmology, online June 20.

The CATT trial found bevacizumab and ranibizumab were similarly effective in improving visual acuity when both were given monthly.

Read the full article.

Related Content